Synopsis

To date, Fibrotech’s non-clinical development program has demonstrated that the FT compounds are potent antifibrotic agents.

In particular, Fibrotech has demonstrated that its lead compound:

• More potently attenuates TGF-β induced collagen synthesis in cultured kidney mesangial cells and cardiac fibroblasts in comparison to tranilast.
• Has high oral bioavailability in the rat, similar to tranilast.
• Shows no evidence of toxicity when administered to rats at three times its therapeutic dose.
• Prevents the development of fibrosis and albuminuria in a well-characterised and clinically predictive rat model of diabetic nephropathy.
• Halts the progression of late stage diabetic nephropathy in a head-to-head comparison with tranilast, while at the same dose tranilast failed to slow progression.
• Delays the progression of fibrosis and renal failure in a non-diabetic model of chronic kidney disease.
• Preserves systolic and diastolic function in both a diabetic and non-diabetic model of heart failure in rodents.